Free Trial

Achieve Life Sciences Q1 2023 Earnings Report

Achieve Life Sciences logo
$4.00 -0.16 (-3.85%)
(As of 04:00 PM ET)

Achieve Life Sciences Earnings Headlines

Achieve Life Sciences Appoints Mark K. Oki as CFO
We recommended Palantir in 2021, now we’re recommending this...
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
Achieve Life Sciences Appoints Mark Oki As New CFO
See More Achieve Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Achieve Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Achieve Life Sciences and other key companies, straight to your email.

About Achieve Life Sciences

Achieve Life Sciences (NASDAQ:ACHV), a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

View Achieve Life Sciences Profile

More Earnings Resources from MarketBeat

Upcoming Earnings